An Evaluation of Three Doses of NS 2330 in Patients With Mild to Moderate Dementia of the Alzheimer's Type

NCT00153010 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

430

Enrollment

INDUSTRY

Sponsor class

Conditions

Alzheimer Disease

Interventions

DRUG: NS 2330 (Tesofensine)

Sponsor

Boehringer Ingelheim